Mail to a Friend

Roche’s Evrysdi® (risdiplam) – the first and only oral treatment for Spinal Muscular Atrophy (SMA), now available in India

2021-09-20 11:45:56 Health and Fitness


29 July 2021, Mumbai, India: Roche today announced the launch of Evrysdi® (risdiplam), the first and only approved treatment in India for Spinal Muscular Atrophy (SMA) patients. Evrysdi® was first approved by the US FDA in August 2020 and is today available in India within 11 months of the US approval. Since its launch, over 4000 SMA patients across 50+ countries have benefitted from Evrysdi®.

About SMA

SMA is a severe, progressive rare neuromuscular disease that can be fatal. It affects approximately one in 10,000 live births globally1 and one in 7744 live births in India2 and is the leading genetic cause of infant mortality. SMA is caused by a mutation of the survival motor neuron 1 (SMN1) gene, which leads to a deficiency of SMN protein. This protein is found throughout the body and is essential to the function of nerves that control muscles and movement. Without it, nerve cells cannot function correctly, leading to muscle weakness over time. Depending on the type of SMA, an individual’s physical strength and their ability to walk, eat or breathe can be significantly diminished or lost.

About Evrysdi® and global clinical trials

Evrysdi® is administered daily at home orally (it is supplied as powder which is constituted into a liquid solution and taken once daily by mouth or feeding tube if required) and is designed to treat SMA by increasing production of the Survival Motor Neuron (SMN) protein. It is approved for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older.

About Roche Products (India) Pvt. Ltd.

Roche Products (India) Private Limited was incorporated in 1994 as a wholly owned subsidiary of the Roche Group, headquartered in Basel, Switzerland. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. For more than 60 years, Roche has been committed to making a difference to the lives of people in India. Today, Roche is the leader in oncology treatment in India; apart from cancer, Roche’s has innovative medicines in other therapy areas too: transplantation, rheumatoid arthritis (RA), and chronic kidney disease (CKD)-related anaemia. Roche believes in making the latest and most innovative medicines accessible to patients in India in the fastest possible time. For more than 50 years, Roche has been developing medicines with the goal to redefine treatment in oncology. Today, Roche is investing more than ever in our effort to bring innovative treatment options that help a person’s own immune system fight cancer.

Company :-SPAG

User :- Tirna Chowdhury



Related Post


Learn about online entrepreneurship at